Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common and deadly malignancies worldwide. Approximately, 80% of patients are initially diagnosed at intermediate or advanced stages, which means that curative therapies are unable to be performed. In most cases, systemic treatment is ineffective, esp...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jin-Tao, Zhang, Shuai, Yang, Yi-Han, Zhang, Zi-Chen, Jiang, Nan, Li, Wan-Ci, Shen, Jian, Zhong, Bin-Yan, Zhu, Xiao-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Interventional Treatment of Hepatocellular Carcinoma (HCC)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661563/
https://www.ncbi.nlm.nih.gov/pubmed/36387611
http://dx.doi.org/10.1177/11795549221134832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661563/
https://www.ncbi.nlm.nih.gov/pubmed/36387611
http://dx.doi.org/10.1177/11795549221134832

Ejemplares similares